A bipartisan group of U.S. lawmakers reintroduced a measure to secure the FDA’s regulation of hemp-derived CBD products. The move comes seven months after the FDA announced it will not regulate CBD products as food and dietary supplements. The goal of the announced subcommittee hearing is to examine the FDA’s failure to regulate hemp-derived and cannabidiol (CBD) products under existing authorities for years. The FDA approved Jazz Pharmaceuticals' Epidiolex, a CBD-based drug for treating severe forms of epilepsy.